Osteogenesis Imperfecta (OI) also known as brittle bone disease, is a genetic disorder that affects the bones. The affected person might experience a bone break (fracture) easily from mild trauma or with no causes. In some severe cases, it may occur even before birth.
As per the National Organization for Rare Disorders, Osteogenesis Imperfecta (OI) type I is estimated to occur in one in 30,000 live births. Osteogenesis Imperfecta (OI) type II is estimated to occur in one in 60,000 live births. The overall prevalence of all types of Osteogenesis Imperfecta (OI) is estimated at .5 per 10,000 individuals in the United States. Around 20,000 to 50,000 people in the United States have Osteogenesis Imperfecta (OI).
Some of the key signs and symptoms of Osteogenesis Imperfecta (OI) includes bone pain, bone deformity, loose joints, brittle teeth, and many others. Osteogenesis Imperfecta (OI) is diagnosed based on DNA tests, X-rays, blood tests or urine tests, or biochemical testing. As per the severity of the condition the Osteogenesis Imperfecta is classified as osteogenesis imperfecta types I, II, and IV.
Get FREE sample copy at:
https://www.delveinsight.com/sample-request/osteogenesis-imperfecta-oi-market
The Osteogenesis Imperfecta (OI) market report also covers emerging drugs, current treatment practices, Osteogenesis Imperfecta (OI) market share of the individual therapies, current and forecasted Osteogenesis Imperfecta (OI) Market Size from 2017 to 2030 segmented by seven major markets.
The report provides a detailed current Osteogenesis Imperfecta (OI) treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the market.
Key Benefits of Osteogenesis Imperfecta (OI) Market Report
-
Osteogenesis Imperfecta (OI) market report provides an in-depth analysis of Osteogenesis Imperfecta (OI) Market Size, Share, Trend, Epidemiology and Market Forecast till 2030, in 7 major markets, i.e. EU5 (Germany, Italy, Spain, France, and the UK), Japan, and the United States.
-
The Osteogenesis Imperfecta (OI) market report will help in developing business strategies by understanding the Osteogenesis Imperfecta (OI) Market trends & developments, key players, and future market competition that will shape and drive the Osteogenesis Imperfecta (OI) market in the upcoming years.
-
The Osteogenesis Imperfecta (OI) market report covers Osteogenesis Imperfecta (OI) current treatment practices, emerging drugs, market share of the individual therapies in 7 MM.
-
The report provides a detailed assessment of the Osteogenesis Imperfecta (OI) market in terms of market drivers & barriers, Unmet Needs, market opportunities, patient population, comparative analysis of pipeline products with detailed clinical profiles, and other factors.
Osteogenesis Imperfecta (OI) Market
The Osteogenesis Imperfecta (OI) market outlook section of the report helps to build a detailed comprehension of the historic, current and forecasted Osteogenesis Imperfecta (OI) market trends by analysing the impact of current therapies on the market, unmet needs, drivers, and barriers, and demand for better technology.
The report gives a thorough detail of the Osteogenesis Imperfecta (OI) market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, and view of the key opinion leaders.
Osteogenesis Imperfecta (OI) Epidemiology
The Osteogenesis Imperfecta (OI) epidemiology section covers insights about the historical and current Osteogenesis Imperfecta (OI) patient pool and forecasted trends for every seven major countries (i.e. the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan from 2017 to 2030.
It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides the diagnosed patient pool and their trends along with assumptions undertaken.
Osteogenesis Imperfecta (OI) Drugs Uptake and Key Market Players
The Osteogenesis Imperfecta (OI) Drugs Uptake section focuses on the rate of uptake of the potential drugs recently launched in the Osteogenesis Imperfecta (OI) market or expected to get launched in the market during the study period. The analysis covers Osteogenesis Imperfecta (OI) market uptake by drugs; patient uptake by therapies; and sales of each drug.
Report’s Drugs Uptake section helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.
Osteogenesis Imperfecta (OI) Companies:
Eli Lilly and Company
Mereo BioPharma Group plc
Celgene Corporation
Amgen Inc
Bone Therapeutics SA
Teva Pharmaceutical Industries
Merck & Co., Inc
And many others.
Table of Content
1. Key Insights
2. Executive Summary
3. Osteogenesis Imperfecta (OI) Competitive Intelligence Analysis
4. Osteogenesis Imperfecta (OI) Market Overview at a Glance
5. Osteogenesis Imperfecta (OI) Disease Background and Overview
6. Osteogenesis Imperfecta (OI) Patient Journey
7. Osteogenesis Imperfecta (OI) Epidemiology and Patient Population
8. Osteogenesis Imperfecta (OI) Treatment Algorithm, Current Treatment, and Medical Practices
9. Osteogenesis Imperfecta (OI) Unmet Needs
10. Key Endpoints of Osteogenesis Imperfecta (OI) Treatment
11. Osteogenesis Imperfecta (OI) Marketed Products
12. Osteogenesis Imperfecta (OI) Emerging Therapies
13. Osteogenesis Imperfecta (OI) Seven Major Market Analysis
14. Attribute Analysis
15. Osteogenesis Imperfecta (OI) Market Outlook (7 major markets)
16. Osteogenesis Imperfecta (OI) Access and Reimbursement Overview
17. KOL Views on the Osteogenesis Imperfecta (OI) Market.
18. Osteogenesis Imperfecta (OI) Market Drivers
19. Osteogenesis Imperfecta (OI) Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
*The table of contents is not exhaustive; the final content may vary.
Related Reports By DelveInsight
Osteogenesis Imperfecta (OI) Epidemiology Forecast
DelveInsight’s Osteogenesis Imperfecta (OI) – Epidemiology Forecast 2030 report delivers an in-depth understanding of the disease, historical, and forecasted epidemiology of Osteogenesis Imperfecta (OI) in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
Osteogenesis Imperfecta (OI) Pipeline Insights
Osteogenesis Imperfecta (OI) Pipeline Insights, 2021 report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across the Osteogenesis Imperfecta (OI) market.
About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end-to-end comprehensive solutions to improve their performance.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: +919650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: www.delveinsight.com/